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Abstract
Rare causal variants are believed to significantly contribute to the genetic basis of common diseases or quantitative
traits. Appropriate statistical methods are required to discover the highest possible number of disease-relevant
variants in a genome-wide screening study. The publicly available Genetic Analysis Workshop 17 data set consists
of 697 individuals and 24,487 genetic variants. It includes a simulated complex disease model with intermediate
quantitative phenotypes. We compare four gene-wise scoring methods with respect to ranking of causal genes
under variable allele frequency thresholds for collapsing of rare variants and considering whether or not rare
variants were included. We also compare causal genes for which the ranks differ clearly between scoring methods
regarding such characteristics as number and strength of causal variants. We corroborated our findings with
additional simulations. We found that the maximum statistics method was superior in assigning high ranks to
genes with a single strong causal variant. Hotelling’s T
2 test was superior for genes with several independent
causal variants. This was consistent for all phenotypes and was confirmed by single-gene analyses and additional
simulations. The multivariate analysis performed similarly to Hotelling’s T
2 test. The least absolute shrinkage and
selection operator (LASSO) analysis was widely comparable with the maximum statistics method. We conclude that
the maximum statistics method is a superior alternative to Hotelling’s T
2 test if one expects only one independent
causal variant per gene with a dominating effect. Such a variant could also be a supermarker derived by collapsing
rare variants. Because the true nature of the genetic effect is unknown for real data, both methods need to be
taken into consideration.
Background
For many common diseases and quantitative traits
investigators have observed a gap between heritability
estimates and the variance explained by common
genetic variants discovered in genome-wide association
studies. Rare and low-frequency causal genetic variants
have been suggested to fill a significant part of this gap
[1]. High-throughput sequencing for the identification of
rare variants is technically feasible now. However, given
t h es i z eo fm o s tc u r r e n ts t u d i e s ,t h el o wf r e q u e n c yo f
rare variants heavily affects the power of single-marker
association tests. Hence it is necessary to either pool
rare variants or combine them with common variants
[1]. The Genetic Analysis Workshop 17 (GAW17) data
set allows comparison of genome-wide screening meth-
ods for both common and rare variants. These methods
should be optimized regarding the enrichment of true
positive variants in gene lists selected for future replica-
tion studies.
In this paper, we compare four scoring methods on
the basis of the GAW17 data set of unrelated individuals
for different analysis parameters (allele frequency cutoffs
for the definition of rare variants and use of rare var-
iants): the maximum statistics method, the LASSO (least
absolute shrinkage and selection operator) method,
Hotelling’s T
2 test, and multivariate analysis. In contrast
to single-marker testing, we focus on identification of
causal genes using gene-wise scores.
We investigate under what conditions each of the
methods performs better. For this purpose, we rank all
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in the high ranking of genes that contain causal variants.
M o r ep r e c i s e l y ,w ep u r s u ea n s w e r st ot h ef o l l o w i n g
questions: (1) Are there differences in the performance
of scoring methods, and if so, why? (2) Does the cutoff
for allele frequency of rare variants have an influence on
the performance? (3) Does inclusion of rare variants
improve the search for causal variants in our data set?
These analyses were accompanied by additional
simulations.
Methods
Data set
Our study is based on the GAW17 data set, as described
e l s e w h e r e[ 2 ] .W ew e r ea w a r eo ft h es i m u l a t i o nm o d e l
and analyzed all 200 simulation data sets of unrelated
individuals.
Data pre-analysis, test statistics, and models
We considered two alternative allele frequency cutoffs
(1% and 5%) to define a variant as rare. We created four
different data sets for analysis: CR1% and CR5% include
all common variants with frequencies above 1% and 5%,
respectively, and incorporate gene-wise collapsing of
nonsynonymous rare variants into a single supermarker,
as described elsewhere [3]. CR1% consists of 7,529
variants with 2,451 genes, and CR5% consists of 4,617
variants with 2,124 genes. For the definition of
gene-wise, we applied the gene annotations provided by
GAW17 [2]. Data sets C1% and C5% are identical to
CR1% and CR5%, respectively, but exclude all rare
variant supermarkers. C1% consists of 6,356 variants
with 2,208 genes, and C5% consists of 3,132 variants
with 1,473 genes. Markers with fewer than five minor
alleles were eliminated to stabilize regression modeling.
Linkage disequilibrium of rare variant supermarkers
with common variants was low ( Rmax .
2 02 3 = ,
R95th percentile
2 00 2 = . for causal markers of CR1%, and
R95th percentile
2 00 5 = . , R95th percentile
2 00 5 = . for causal
markers of CR5%).
Using linear and logistic regression techniques, we
analyzed the following three endpoints: traits Q1, Q2,
and affected status (AFF) adjusted for Q1, Q2, and Q4.
Analysis of Q1 was adjusted on Q2 and vice versa to
reduce variance as much as possible according to the
simulated model. In addition, all three endpoints were
adjusted for age, sex, and smoking status. We assumed
an additive genetic model throughout.
The maximum statistics method was performed by
calculating all marginal models of a gene, including
those of the rare variant supermarker, if applicable.
The maximum of the t-statistic was used as the score
for a gene. For Hotelling’s T
2 test, marginal models
were combined using Hotelling’s T
2 calculated on the
basis of the correlation matrix of the markers. Multivari-
ate analysis was calculated for each gene by performing
a likelihood ratio test between the model with all
g e n e t i cm a r k e r so fag e n ea n dt h en u l lm o d e lw i t h o u t
any genetic effects. For the LASSO method, we applied
the R routine glmnet with standard attributes of version
1.5.2 (R 2.11.0, http://www.r-project.org). The tuning
parameter was determined by means of cross-validation,
as recommended by Friedman et al. [4]. The shrunken
model was compared with the null model using the like-
lihood ratio test. Only genetic markers were shrunk.
Genes were ranked according to their summary statis-
tics. Analyses were repeated for each of the 200 simula-
tion replicates in the GAW17 data set.
Assessment of regression analysis results and additional
simulations
We defined cutoff values of 10, 20, 50, 100, 200, and
500 best-ranked genes for inclusion in a potential repli-
cation study. The average number of phenotype-specific
causal genes in each of these gene lists was calculated
over all 200 simulations.
To determine which of the analysis parameters
(method, cutoff for rare variants, inclusion of rare var-
iants) were favorable, we compared the numbers of
identified causal genes between scenarios using multi-
variate mixed model analysis (SAS 9.1.3). Method, cutoff
for rare variants, use of rare variants, and the cutoff-use
interaction were treated as fixed factors. The simulation
scenario was treated as a random factor. This analysis
was done separately for all gene list cutoffs and
phenotypes.
To identify conditions that influence performance of
the scoring methods, we analyzed the following para-
meters for each causal gene: number and percentage of
causal and noncausal common and rare variant super-
markers; effect sizes of the supermarkers (b coefficient
multiplied by the standard deviation of the allele fre-
quency); frequencies and effect sizes of the second
strongest variant; and relative size of the second stron-
gest effect. We compared these characteristics between
genes for which the methods performed differently as
defined by a ratio of median ranks greater than 1.1 or
smaller than 0.9. A gene was included in this analysis
only if its rank was greater than 1,000 for at least one
method. Otherwise, it was considered undetectable.
In addition, we simulated a set of 2,000 genes without
genetic effect containing two, three, five, or seven com-
mon or collapsed markers, each with allele frequencies
d r a w nf r o mt h eu n i f o r md i s t r ibution. For an additional
gene we assumed a causal effect of one, two, or three
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quency (1%, 5%, 10%, 20%, or 40%) and odds ratio (1.2,
1.3, 1.5, or 1.7). This causal gene was simulated 1,000
times. We considered samples of N = 300 or N = 1,000
case subjects and an equal number of control subjects.
Ranks of the causal gene were compared between
methods.
Results
Analysis of best-ranked genes for analysis scenarios
The observed frequencies of causal genes were signifi-
cantly higher than expected at random for all analysis
scenarios except for the C5% data set at the gene list
cutoff of N = 500. Using, for example, a cutoff of 200
top genes and averaging over all 200 replicates, we dis-
covered 2.2–3.6, 2.6–6.1, and 2.3–3.2 causative genes for
Q1, Q2, and AFF, respectively, depending on the analy-
sis setting. Scoring method, cutoff for rare variants, and
inclusion of rare variant supermarkers significantly influ-
enced the performance of analyses.
The results of multivariate analyses are summarized
in Table 1. A 5% allele frequency cutoff was advanta-
geous for Q1, for selection of a low number of genes,
a n df o rA F Ft h r o u g h o u tb u tn o tf o rQ 2 .A n a l y s i so f
rare variant supermarkers strongly improved the power
of Q1 and Q2 analyses but not the power of AFF
analysis. For Q1 and Q2 but not for AFF there was a
strong interaction of allele frequency and use of rare
variants, favoring the 1% cutoff if rare variants were
excluded. As expected, Hotelling’s T
2 test and multi-
variate analysis performed similarly. The maximum
statistics and LASSO methods also mostly showed
similar performance. Either the maximum statistics
method or Hotelling’s T
2 test outperformed the other
methods in most scenarios. Compared to Hotelling’s
T
2 test, the maximum statistics method performed bet-
ter for longer gene lists. This effect was more pro-
nounced for Q2 and AFF than for Q1.
Detailed characterization of detectable causal genes and
additional simulations
To understand this behavior in more detail, we deter-
mined the median ranks of all causal genes for each data
set and each method over all 200 simulation replicates.
Genes that were better detected using the maximum
statistics method compared to Hotelling’s T
2 test were
characterized by a higher number of markers per gene, a
lower relative frequency of causal variants, and often a
lower effect size of the strongest variant. Genes that were
better detected using the maximum statistics method
compared to the LASSO method also showed a lower
effect size of the strongest variant and weaker relative
effects of the second strongest variant. An overview of all
characteristics can be found in Table 2.
To further validate our findings, we performed simula-
tions with varying genetic effects of a single causal gene.
Nearly independent of sample size, effect size, and num-
ber of markers in a gene, the maximum statistics
method was better than Hotelling’s T
2 test if there was
only one causal variant per causal gene. In contrast, if
there were two or more independent variants, the maxi-
mum statistics method was outperformed by Hotelling’s
T
2 test (results not shown).
Discussion
In our study, we compared different scoring methods
for the combined analysis of common variants and
rare variants on the basis of a simulated data set of the
GAW17 consortium. The data set was considered
representative of genome-wide screening studies that
endeavor to select candidate genes for subsequent
replication studies. Therefore we focused on gene-wise
scoring to define ranked lists of genes for future repli-
cation. We considered the ranking of causal genes
under variable scoring methods, allele frequency
thresholds for collapsing rare variants, and the inclu-
sion or not of rare variants. Scoring methods per-
formed differently in different scenarios. There was no
single best method that was superior in all situations.
For all phenotypes, either the maximum statistics
method or Hotelling’s T
2 test outperformed the other
scoring methods.
Our analysis was based on ranking the statistics and
selecting a certain number of best-ranked genes instead
of calculating and interpreting p-values. This approach
is equivalent to genomic control [5]. Furthermore, the
analysis of ranks rather than p-values allows us to make
fair comparisons of the scoring methods studied even if
the methods differ in the degree of p-value inflation.
This approach worked well in our analysis in the sense
that causal genes were clearly enriched in higher ranks
of our gene lists.
However, to be confident of our results, we per-
formed a series of complementary analyses. First, we
calculated permutation-test-based p-values for each
scoring method, analyzing Q1 and Q2 of simulation
replicate 1. This procedure yielded interpretable p-
values and essentially resulted in the same ranking of
causal genes as the procedure without permutation
(not shown). Second, we repeated most of our analyses
applying rigorous quality control. For this purpose, we
removed a set of 695 spuriously associated genes from
t h eo r i g i n a lG A W 1 7d a t as e t ,a sp r o p o s e db yL u e d t k e
et al. [6]. In addition, we adjusted statistics for popula-
tion stratification and filtered out SNPs that violated
Hardy-Weinberg equilibrium. The results were essen-
tially the same as those without quality control (data
not shown).
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Page 3 of 7Table 1 Results of mixed model analysis of the ranked gene lists for all phenotypes
Phenotype Gene list cutoff (N) MS vs. HT MS vs. MV MS vs. LA HT vs. MV HT vs. LA MV vs. LA AF = 1% vs. AF = 5% CV vs. RV IA AF = 1% and CV
Q1 10 −0.27*** −0.25*** −0.15*** 0.02 0.13*** 0.10*** −0.18*** −0.73*** 0.43***
20 −0.19*** −0.18*** −0.11*** 0.01 0.08*** 0.07*** −0.10*** −0.71*** 0.45***
50 −0.14*** −0.12*** −0.03 0.02 0.11*** 0.09*** 0.01 −0.66*** 0.51***
100 −0.05 −0.03 0.06* 0.02 0.11*** 0.09** 0.10*** −0.77*** 0.76***
200 −0.01 0.01 0.11*** 0.02 0.12*** 0.10*** 0.21*** −1.09*** 1.07***
500 0.08* 0.09** 0.13*** 0.01 0.05 0.04 0.42*** −2.00*** 1.85***
Q2 10 −0.04 −0.06 0.03 −0.02 0.07* 0.09** 0.14*** −0.67*** 0.32***
20 −0.03 −0.03 −0.04 −0.00 −0.01 −0.01 0.14*** −1.05*** 0.46***
50 0.08 0.07 −0.01 −0.01 −0.09* −0.08* 0.26*** −1.69*** 0.56***
100 0.14** 0.13** −0.00 −0.01 −0.14** −0.14** 0.22*** −2.32*** 0.72***
200 0.11* 0.12* 0.04 0.01 −0.07 −0.08 0.03 −3.14*** 1.13***
500 0.25*** 0.25*** 0.11* 0.00 −0.13* −0.13* 0.18*** -3.88*** 1.19***
AFF 10 0.03 −0.01 0.04** −0.04* 0.02 0.06*** −0.15*** 0.02 −0.03
20 0.09*** 0.08*** 0.05** −0.01 −0.04* −0.03 −0.16*** 0.03 −0.03
50 0.16*** 0.14*** 0.03 −0.02 −0.13*** −0.11*** −0.14*** 0.03 −0.05
100 0.34*** 0.29*** 0.11*** −0.05 −0.23*** −0.18*** −0.13*** 0.14*** −0.16***
200 0.44*** 0.34*** 0.07 −0.10* −0.37*** −0.27*** −0.20*** 0.21*** −0.25***
500 0.69*** 0.60*** 0.15*** −0.09* −0.54*** −0.45*** −0.40*** 0.39*** −0.33***
N is the cutoff value of the ranked gene lists for inclusion in a future replication study. MS, maximum statistics method. HT, Hotelling’s T
2 test. MV, multivariate analysis. LA, LASSO method. AF, cutoff for allele
frequency denoting rare variants. CV, analysis of common variants alone. RV, analysis of both common and collapsed rare variants. IA = interaction term. For the comparisons, values denote the average difference in
number of detected causal genes. Negative numbers indicate a lower number of causal genes under the first setting. Significant positive and negative effects are in boldface and italics, respectively.
* p < 0.05.
** p < 0.01.
*** p < 0.001.
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7Table 2 Characteristics of genes for which gene-wise scoring methods performed differently
MS vs. HT MS vs. LA
CR1% CR5% CR1% CR5%
MS better HT better p-
value
MS better HT better p-
value
MS better LA better p-
value
MS better LA better p-
value
Rank (MS)/rank (other method) 0.53 (0.14) 2.4 (2.56) 0.56 (0.15) 1.43 (0.31) 0.7 (0.23) 3.09 (3.81) 0.72 (0.58) 1.41 (0.34)
Genes with better ranks 13/27 8/27 12/29 13/29 7/27 4/27 7/29 5/29
Markers per gene 5.8 (2.6) 2 (0.8) <0.001 4.8 (2.1) 1.5 (0.9) <0.001 4.3 (2.7) 5.8 (4.9) 4.2 (2.2) 2.2 (1.1)
Causal SNPs per gene (number) 1.3 (0.5) 1.4 (0.7) 1.1 (0.3) 1.2 (0.4) 1.4 (0.5) 2.5 (1.3) 1.2 (0.4) 1.6 (0.5)
Causal SNPs/gene (%) 25.6 (11.6) 72.9 (29.5) 0.002 26 (10.7) 88.5 (21.9) <0.001 42.8 (27.9) 68.4 (40) 39.6 (32) 80 (27.4)
Frequency-adjusted effect size of strongest
variant
0.038
(0.024)
0.044
(0.023)
0.025
(0.02)
0.048
(0.025)
0.02 0.033
(0.022)
0.05 (0.023) 0.025
(0.022)
0.066
(0.028)
0.03
Frequency of strongest variant 0.047
(0.077)
0.053
(0.071)
0.046
(0.07)
0.049 (0.06) 0.066
(0.103)
0.083
(0.065)
0.085
(0.103)
0.077
(0.063)
Relative effect size of second strongest variant
(%)
40.5 (29.8) 63.6 (51.3) 10.9 (NA) 54.5 (23.5) 34 (20.4) 87.9 (10.4) 0.03 10.9 (NA) 54.5 (23.5)
MS, maximum statistics method. HT, Hotelling’s T
2 test. LA, LASSO method. CR1% are CR5% the data sets with rare variants using a 1% or a 5% cutoff of allele frequency, respectively. Means and standard deviations
are presented. p-values are based on a two-group t-test. Characteristics that show significant differences in CR1% as well as in CR5% are in boldface.
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7We used the simplest method, proposed by Li and
Leal [3], for collapsing rare variants. Numerous more
sophisticated collapsing methods are currently available.
However, they performed essentially equally well on a
gene-wise level for the GAW17 data set (see GAW17,
Group 15). A plausible explanation is that only a rela-
tively small number of individuals carried more than
one rare variant per gene and that all modeled effects
were deleterious.
In our analysis, we collapsed only nonsynonymous
rare variants to enrich direct causal effects. In contrast,
we used all common variants for analysis, including
synonymous common variants. Although only nonsy-
nonymous common variants were causal in the simula-
tion model, synonymous common variants may provide
information because of linkage disequilibrium with cau-
sal variants. This approach is similar to an experimental
design in which a SNP microarray-based study is
accompanied by additional sequencing data.
We used four scoring methods to combine the evidence
of all markers (common variant and rare variant super-
marker): the maximum statistics method, Hotelling’s T
2
test, multivariate analysis, and the LASSO method. Hotell-
ing’s T
2 test and multivariate analysis are established
methods specially designed to combine the evidence of
correlated tests. In contrast, the maximum statistics
method does not consider this correlation structure. The
null distribution of the maximum statistics method is a
complex order statistic that makes calculating the p-values
a nontrivial task. We performed no adjustments of the
maximum statistics in order to account for the number of
m a r k e r sp e rg e n e .T h i si sa n a l o g o u st os e l e c t i n gs i n g l e
markers in the screening stage of a common multistage
genome-wide association study. Furthermore, correcting
for the number of markers in a gene did not improve the
results of the maximum statistics method in the GAW17
data set (results not shown).
Methodically, the LASSO method can be considered to
be in between the maximum statistics method and multi-
variate analysis because it selects a genetic model first. As
shown in Table 1, the LASSO method offered no advan-
tage in our analysis because it was outperformed by
either the maximum statistics method or Hotelling’s T
2
test. Among all investigated scoring methods, the LASSO
method is the most computationally expensive.
We aimed to characterize conditions under which
Hotelling’s T
2 test and the maximum statistics method
performed differently. For this purpose, we considered
median ranks of causal genes and compared characteris-
tics of those genes for which the ranks differ clearly
between methods. We found that the maximum statistics
method performed particularly well in genes with a high
number of markers but a low number of causal variants
(Table 2). This was corroborated by additional
simulations that eliminated all possible confounding fac-
tors. An explanation for this observation is as follows:
Hotelling’s T
2 test statistics are designed to detect several
(smaller) deviations from the marginal null hypotheses.
This implies that Hotelling’s T
2 test does not perform
equally well in detecting single deviations that may be
blurred by the noise of other null markers.
Conclusions
We conclude that the maximum statistics method is a
superior scoring alternative to Hotelling’s T
2 test if one
expects only one independent causal variant per gene
with a dominating effect. Because the true nature of the
genetic effect is unknown for real data, both methods
need to be taken into consideration. Future work is
necessary to investigate how both scoring methods can
contribute to the search for genetic modifiers of traits.
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